Zobrazeno 1 - 10
of 166
pro vyhledávání: ''
Publikováno v:
International Journal of Molecular Medicine
Acute kidney injury (AKI) is characterized by an abrupt deterioration of renal function. Formononetin (FOR) protects against cisplatin (CIS)‑induced AKI, and it has various potential pharmacological and biological effects, including anti‑inflamma
Autor:
Radu Vidra, Snejeana Tintari, Tudor Ciuleanu, Adina Nemes, Andrada Deac, Andreea Vidrean, Sebastian Pintea
Publikováno v:
Experimental and Therapeutic Medicine
The addition of platinum compounds to standard neoadjuvant chemotherapy (NACT) for triple-negative breast cancer (TNBC) is highly controversial. Platinum agents, such as cisplatin and carboplatin, are DNA-damaging agents which exhibit activity in bre
Publikováno v:
Experimental and Therapeutic Medicine
Ovarian cancer (OC) is one of the prominent causes of mortality in female patients diagnosed with gynecologic malignancies. While it has previously been demonstrated that apigenin inhibits cell growth in colon and breast cancer cells, the effect of a
Autor:
Shuangyue Liu, Dongyan Bao, Tao Xu, Tingting Ma, Yang Di, Li Yu, Yan Wang, Donghao Qu, Yuan Tian, Aimei Wang, Yuhan Lin
Publikováno v:
International Journal of Molecular Medicine
Cisplatin (CDDP) is widely used in clinical settings for the treatment of various cancers. However, ototoxicity is a major side effect of CDDP, and there is an associated risk of irreversible hearing loss. We previously demonstrated that CDDP could i
Publikováno v:
Oncology Letters
The emergence of resistance to chemotherapy drugs in patients with ovarian cancer is still the main cause of low survival rates. The present study aimed to identify key genes that may provide treatment guidance to reduce the incidence of drug resista
Publikováno v:
International Journal of Molecular Medicine
Sphingosine-1-phosphate (S1P) serves an important role in various physiological and pathophysiological processes, including the regulation of cell apoptosis, proliferation and survival. Sphingosine kinase 1 (SPHK1) is a lipid kinase that phosphorylat
Autor:
Hirotake Hida, Mariko Nakamura, Yuna Shiroma, Miku Iwata, Akira Yoshimi, Masayuki Miyazaki, Noriko Tanaka, Aya Torii-Goto, Yukihiro Noda, Kiyofumi Yamada
Publikováno v:
Mol Clin Oncol
Chemotherapy-induced nausea and vomiting (CINV) can cause anorexia, weight loss and deterioration of patient quality of life. It is one of the most unpleasant adverse effects of chemotherapy treatment regimens. For the optimal treatment of gastrointe
Publikováno v:
Oncology Reports. 46
Molecular-targeted therapy has shown promise as a treatment for advanced osteosarcoma (OS). Sorafenib (SOR), a multikinase inhibitor, is the approved systemic drug of choice for OS, but has demonstrated limited benefits due to its toxicity and other
Autor:
Ming Ding, Jing Huang, Ying Wu, Shuhua Han, Ping-Sheng Chen, Yan Xie, Su-Fang Yang, Xiaoli Zhu
Publikováno v:
Oncology Letters
Radioactive seed brachytherapy is a method for treating drug-resistant, late-stage non-small cell lung cancer (NSCLC). To elucidate the mechanism of low-dose gambogic acid (GA) and NaI131 in drug-resistant NSCLC cells, the human NSCLC A549 cell line
Publikováno v:
Oncology Letters
Drug resistance hinders effectiveness of human ovarian cancer (OC) therapies, such as cisplatin or paclitaxel therapy. Although dacomitinib, a novel anticancer agent is used against multiple types of cancers, such as non-small cell lung cancer, head